SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
Website: www.sinobiopharm.com
(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
ENTER INTO STRATEGIC PARTNERSHIP WITH BOEHRINGER INGELHEIM ON INNOVATIVE ONCOLOGY PORTFOLIO IN CHINA

The board of directors (the "**Board**") of Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that the Group entered into a strategic partnership with Boehringer Ingelheim to bring Boehringer Ingelheim's innovative cancer therapies to the market in mainland China.

Under the agreement, the Group and Boehringer Ingelheim (the "**Parties**") will collaborate to jointly develop and commercialize Boehringer Ingelheim's oncology pipeline in mainland China. The strategic partnership covers multiple assets under clinical development by Boehringer Ingelheim, including three assets brigimadlin, zongertinib, and BI 764532, and multiple early-stage assets. The Parties will join efforts to bring these oncology products to patients in mainland China, with the Group consolidating the revenue for the products in China.

Introduction of major assets under clinical development:

Brigimadlin is a mouse double minute 2 (MDM2)-p53 antagonist which has advanced into the pivotal trial for the treatment of dedifferentiated liposarcoma (DDLPS) and is being investigated for other cancers such as biliary tract cancer (BTC), non-small cell lung cancer (NSCLC), pancreatic cancer and other tumors with MDM2 amplifications.

Zongertinib is a selective human epidermal growth factor receptor 2 (HER2) inhibitor that covalently binds to the tyrosine kinase domain (TKD) of both wild type and mutated HER2 receptors, including those with an exon 20 mutation. Improved selectivity of a HER2 tyrosine kinase inhibitor (TKI) may result in better tolerability and efficacy.

BI 764532 is a delta-like canonical Notch ligand 3/cluster of differentiation 3 (DLL3/CD3) bispecific T-cell engager, which is currently in Phase II clinical study investigating for the treatment of small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).

The Group's strategic partnership with Boehringer Ingelheim is of great significance:

The strategic partnership is expected to enrich the Group's oncology portfolio with innovation from Boehringer Ingelheim's oncology pipeline, and help fulfill unmet clinical needs in China. The strategic partnership also expands the Group's horizons, recognizes the Group's strong commercial capabilities, and makes the Group a preferred partner for MNCs.

Oncology is the largest therapeutic area of the Group. The agreement marks the beginning of the Group's strategic partnership with Boehringer Ingelheim.

About Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at http://www.boehringer-ingelheim.com/.

About brigimadlin

Brigimadlin (BI 907828) is a highly potent, orally available MDM2-p53 antagonist. Brigimadlin binds to MDM2 and blocks the interaction between MDM2 and p53. This prevents MDM2 from inactivating p53, thereby restoring p53 function. Stabilization of p53 leads to TP53 target gene induction that subsequently leads to cell cycle arrest or apoptosis in tumor cells with TP53 wild type status.

Several clinical trials of brigimadlin are ongoing, including a Phase II/III trial evaluating brigimadlin vs doxorubicin as the first-line treatment in patients with advanced DDLPS; a Phase II trial evaluating brigimadlin in patients with BTC and other solid tumors (pancreatic, urothelial, lung); a Phase 0/Ia trial evaluating brigimadlin in combination with radiation therapy in glioblastoma.

Brigimadlin was granted Fast Track Designation by the United States Food and Drug Administration (FDA) for the treatment of DDLPS, and Orphan Drug Designation for the treatment of BTC.

Learn more at https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/mdm2-p53-antagonist.

About zongertinib

Zongertinib (BI 1810631) is a selective HER2 inhibitor that covalently binds to the TKD of both wild type and mutated HER2 receptors, including those with an exon 20 mutation. Improved selectivity of a HER2 TKI may result in better tolerability and efficacy.

Zongertinib is currently undergoing a global Phase I trial as a monotherapy in patients with advanced or metastatic solid tumors. Phase Ia is investigating the pharmacokinetics and safety of zongertinib in patients with solid tumors harboring HER2 aberrations. Phase Ib is investigating safety and efficacy in patients with NSCLC harboring HER2 mutations.

Zongertinib was granted Fast Track Designation by the United States FDA as an investigational oral treatment for patients with NSCLC whose tumors have a HER2 mutation and with disease progression on or after platinum-based therapy.

Learn more at https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/her2-tki.

About BI 764532

BI 764532 is a DLL3/CD3 T-cell engager. DLL3/CD3 T-cell engager acts as a bridge that directs the activity of cytolytic T cells selectively to DLL3-expressing tumors.

BI 764532 is being evaluated in patients with SCLC and NECs in Phase I and II studies. Preclinical results have shown that DLL3/CD3 monotherapy potently inhibited tumor growth in DLL3-positive SCLC xenograft models in a dose-dependent and time-dependent manner. It also modulated the inflammatory environment in the tumor tissue by redirecting CD4-positive ($CD4^+$) and CD8-positive ($CD8^+$) T-cell toward DLL3-positive SCLC cells, without affecting DLL3-negative target cells.

BI 764532 was granted Fast Track Designation by the United States FDA in advanced or metastatic large-cell neuroendocrine carcinoma of the lung (LCNEC-Lung) expressing DLL3 whose disease has progressed following at least one prior line of treatment including platinum-based chemotherapy, Fast Track Designation in extensive stage SCLC (ES-SCLC) with disease progression following at least two prior lines of treatment including platinum-based chemotherapy, and for extrapulmonary NEC (EP-NEC) with advanced or metastatic disease following at least one prior line of treatment including platinum-based chemotherapy, and Orphan Drug Designation for SCLC.

Learn more at https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/dll3-cd3-t-cell-engager.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 8 April 2024

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.